Abstract
Question CAPS are autoinflammatory diseases characterized by recurrent episodes of fever and systemic inflammation, subdivides into three different severity phenotypes (FCAS, MWS, CINCA). These syndromes are caused by mutations of NLRP3 gene coding for an intracellular multiprotein complex that mediates IL-1b processing and secretion. These mutations are gain-of-function, resulting in an inflammasome hyperactivity and IL-1b hypersecretion. We aimed to: increase the knowledge on pathologic consequences of NLRP3 mutations in CAPS patients; understand the molecular and regulatory mechanisms of CAPS disease; identify novel molecular targets for the treatment of cryopyrin/NLRP3 related disorders.
Highlights
Question Cryopyrin associated periodic syndromes (CAPS) are autoinflammatory diseases characterized by recurrent episodes of fever and systemic inflammation, subdivides into three different severity phenotypes (FCAS, MWS, CINCA)
Question CAPS are autoinflammatory diseases characterized by recurrent episodes of fever and systemic inflammation, subdivides into three different severity phenotypes (FCAS, MWS, CINCA)
These syndromes are caused by mutations of NLRP3 gene coding for an intracellular multiprotein complex that mediates IL-1b processing and secretion
Summary
Question CAPS are autoinflammatory diseases characterized by recurrent episodes of fever and systemic inflammation, subdivides into three different severity phenotypes (FCAS, MWS, CINCA). These syndromes are caused by mutations of NLRP3 gene coding for an intracellular multiprotein complex that mediates IL-1b processing and secretion. These mutations are gain-of-function, resulting in an inflammasome hyperactivity and IL-1b hypersecretion. We aimed to: increase the knowledge on pathologic consequences of NLRP3 mutations in CAPS patients; understand the molecular and regulatory mechanisms of CAPS disease; identify novel molecular targets for the treatment of cryopyrin/NLRP3 related disorders
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
